A Randomized, Parallel Group, Multicenter, Double -Blind, Double-dummy, Placebo-controlled Phase 3 Study With Beclomethasone Dipropionate HFA at 100 μg, 200 μg and 400 μg Daily Doses Compared to Placebo in Mild or Moderate Persistent Asthma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Beclometasone (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Adamis Pharmaceuticals Corporation
Most Recent Events
- 15 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Mar 2019 According to an Adamis Pharmaceuticals Corporation media release, the company expects to initiate the enrollment in this study in 2019.
- 13 Feb 2019 New trial record